Suchergebnisse - "Dexamethasone"

PubPharm (16)

1

Efficacy and safety of systemic, high-dose glucocorticoid therapy for idiopathic sudden sensorineural hearing loss : Study protocol for a three-armed, randomized, triple-blind, multicenter trial (HODOKORT)

enthalten in: HNO | 2022

von Plontke, S. | Girndt, M. | Meisner, C. | +4

2

Efficacy and safety of systemic, high-dose glucocorticoid therapy for idiopathic sudden sensorineural hearing loss

enthalten in: HNO | 2022

von Plontke, S. | Girndt, M. | Meisner, C. | +4

3

Efficacy and safety of systemic, high-dose glucocorticoid therapy for idiopathic sudden sensorineural hearing loss

enthalten in: HNO | 2022

von Plontke, S. | Girndt, M. | Meisner, C. | +4

4

Efficacy and safety of systemic, high-dose glucocorticoid therapy for idiopathic sudden sensorineural hearing loss

enthalten in: HNO | 2022

von Plontke, S. | Girndt, M. | Meisner, C. | +4

5

Tocotrienols : Exciting Biological and Pharmacological Properties of Tocotrienols and other Naturally Occurring Compounds, Part I

enthalten in: Annals of clinical case reports | 2022

von Qureshi, A.

6

The effects of perioperative dexamethasone on eicosanoids and mediators of inflammation resolution : A sub-study of the PADDAG trial

enthalten in: Prostaglandins, leukotrienes, and essential fatty acids | 2021

von Barden, A. | Phillips, M. | Shinde, S. | +2

7

Antiemetic doses of dexamethasone and their effects on immune cell populations and plasma mediators of inflammation resolution in healthy volunteers

enthalten in: Prostaglandins, leukotrienes, and essential fatty acids | 2018

von Barden, A. | Phillips, M. | Hill, L. | +7

8

Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma

enthalten in: Journal of clinical oncology | January 17, 2018

von Siegel, D. | Dimopoulos, M. | Ludwig, H. | +7

9

Bridging the Divide : An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance

enthalten in: Clinical journal of the American Society of Nephrology : CJASN | 2016

von Hogan, J. | Weiss, B.

10

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR) : a randomised, phase 3, open-label, multicentre study

enthalten in: The lancet / Oncology | 2016

von Dimopoulos, M. | Goldschmidt, H.